NASA and SpaceX Launch Crew-13 to International Space Station, While Major Conferences Highlight Advances in Longevity and Dermatology

The reported developments are primarily positive scientific and technological advancements, with no immediate negative risks or significant controversies reported today.

📌 Key developments

• Space Mission to International Space Station Launched NASA and SpaceX are targeting today, October 1, 2026, for the launch of the Crew-13 mission to the International Space Station (ISS) from Cape Canaveral Space Force Station in Florida. The Dragon spacecraft is expected to reach the orbiting laboratory in a record-breaking 7 hours and 50 minutes, which would make it the fastest U.S. spacecraft journey to the ISS in history. The crew includes NASA astronauts Jessica Watkins (commander) and Luke Delaney (pilot), Canadian Space Agency (CSA) astronaut Joshua Kutryk, and Roscosmos cosmonaut Sergey Teteryatnikov (both mission specialists). This mission is important for continuing scientific research and technological development aboard the ISS. It does not, however, prove any new space travel capabilities beyond the established parameters of the Dragon spacecraft.
• Major Longevity Research Conference Begins at Harvard The 13th Aging Research & Drug Discovery (ARDD) Meeting, the world's largest conference dedicated to longevity biotechnology, is taking place from October 1-3, 2026, at Harvard University. This event highlights the field's transition from theoretical concepts to mainstream medicine, with top pharmaceutical companies actively developing commercial programs targeting age-associated diseases such as fibrosis (scarring of tissues), immunology (the study of the immune system), central nervous system (CNS) conditions like Alzheimer's, cardiometabolic diseases (heart and metabolism-related), anti-muscle wasting, and cellular rejuvenation (restoring youthful function to cells). This matters because it signifies a growing focus on interventions to extend healthy human lifespan, a widely desired goal, particularly for conditions like Alzheimer's and heart disease. The conference itself is a platform for discussion and collaboration, not a direct announcement of new treatments, so it does not yet prove the efficacy or availability of specific new therapies.
• New Data on Hair Loss and Skin Disease Treatments Presented At the European Academy of Dermatology and Venereology (EADV) Congress 2026, Nektar Therapeutics presented new Phase 2b data for rezpegaldesleukin, a novel regulatory T cell stimulator, in patients with severe-to-very-severe alopecia areata (an autoimmune condition causing hair loss) and atopic dermatitis (a type of eczema). The data included 6-month off-treatment results showing the durability of response for alopecia areata. Separately, AbbVie showcased new clinical evidence for upadacitinib (brand name RINVOQ), which is already indicated for severe alopecia areata in adults and adolescents, as well as for vitiligo (a condition causing loss of skin pigment). These developments are important as they offer continued progress and potential new options for widely feared conditions like hair loss. However, rezpegaldesleukin is still an investigational drug in Phase 2b trials, meaning it is several years away from potential approval and availability, and its long-term safety and efficacy are still being evaluated.
• AI Advances in Enterprise Software Development and Disease Forecasting IBM today announced self-hosted deployment for IBM Bob, an agentic software development platform that uses artificial intelligence (AI) to assist with software delivery and modernization. This allows enterprises, especially those in regulated industries, to use AI for sensitive code and data within their own controlled infrastructure, addressing security and compliance concerns. In another AI breakthrough, Google's AI-built flu forecasting model was ranked #1 by the Centers for Disease Control (CDC) for accurately predicting flu-related hospital admissions during the 2025-26 season. These advancements matter because they demonstrate AI's growing practical applications in improving efficiency in complex industries and enhancing public health preparedness. While IBM Bob offers greater control, it does not eliminate the need for human oversight in software development, and Google's flu model is a forecasting tool, not a preventative measure or cure.
• Genetic Mapping of Maize for Improved Nutrition A new analysis published today in the Journal of Advanced Research has comprehensively mapped the genetic architecture that controls the trade-off between starch quality, protein quality, and grain yield in maize (corn). This research integrated hundreds of genetic loci (specific locations on a chromosome), dozens of cloned genes, and multi-omics networks (multiple biological data sets) to create a framework for breeding. This is significant because maize is a staple crop globally, and this understanding could lead to the development of new maize lines that are simultaneously heavier, starchier, and more nutritious, addressing food security and nutritional needs. This is fundamental research and does not yet prove the immediate availability of new maize varieties, as further validation and breeding efforts are required.
• Graphene Shows Multiple Superconducting States Researchers from MIT and the University of Basel reported in the journal Nature that rhombohedral graphene, a natural structure consisting of four or five atomically thin layers of carbon atoms, can host multiple superconducting states. Superconductivity is an electronic state where electrons pair up and move through a material with zero resistance. Unusually, some of these new superconducting states in rhombohedral graphene were found to persist and even strengthen in the presence of a magnetic field, which typically destroys superconductivity. Separately, researchers from Tohoku University published in Science Advances that they created a stable version of 'boron graphene' on a three-dimensional crystal surface, revealing a new quantum liquid crystal state. These findings are important for fundamental physics and could pave the way for more energy-efficient electronic devices and potentially high-temperature superconductors, which would revolutionize technology. However, these are laboratory discoveries and do not yet prove immediate real-world applications or commercial viability; they are years away from practical use.
• Self-Sampling HPV DNA Testing Boosts Cervical Cancer Screening in Rural India A new district-level implementation study published in BMC Public Health demonstrates that human papillomavirus (HPV) DNA testing, delivered through self-sampling kits, frontline health workers, and a hybrid of laboratory platforms, can be effectively integrated into routine government services in rural India. This is crucial because cervical cancer is a major public health challenge in India, and screening coverage has been low. HPV DNA testing is the preferred method for cervical cancer screening recommended by the World Health Organization (WHO). This study provides a blueprint for scaling up screening in resource-constrained areas, which is vital for preventing a widely feared cancer. The study proves the feasibility of this approach in a specific region, but does not guarantee its successful implementation or widespread adoption across all diverse rural communities without sustained effort and resources.
• FDA Issues Warnings on Unsafe and Misleading Supplements In 2026, the U.S. Food and Drug Administration (FDA) continued to issue warning letters and safety alerts for dietary supplements. These warnings were triggered by products containing undeclared pharmaceutical ingredients (like stimulants or anabolic steroids), making illegal disease claims (e.g., 'treats arthritis'), or having inaccurate ingredient levels (e.g., melatonin levels far above label claims). This highlights the ongoing challenge of ensuring supplement safety and accurate labeling, and the importance of consumers exercising caution. This information serves as a reminder of regulatory oversight and does not introduce new supplement claims or findings, but rather reinforces the need for strong evidence and proper regulation in the supplement industry.

💡 Why it matters

These developments are crucial for advancing human health, particularly in areas like aging, chronic diseases, and conditions like hair loss and dementia, which are widely feared. Progress in AI and materials science promises to enhance diagnostic capabilities, treatment efficacy, and fundamental understanding of the physical world, impacting various sectors from medicine to space exploration.

🎭 People in the news

• Jessica Watkins — NASA astronaut and commander of the Crew-13 mission to the International Space Station, set to launch today.
• Luke Delaney — NASA astronaut and pilot of the Crew-13 mission to the International Space Station, set to launch today.
• Joshua Kutryk — Canadian Space Agency astronaut and mission specialist for the Crew-13 mission to the International Space Station, set to launch today.
• Sergey Teteryatnikov — Roscosmos cosmonaut and mission specialist for the Crew-13 mission to the International Space Station, set to launch today.
• Alex Zhavoronkov — CEO of Insilico Medicine, an organizer and sponsor of the 13th Aging Research & Drug Discovery (ARDD) Meeting at Harvard University.
• Long Ju — Lawrence C. and Sarah W. Biedenharn Associate Professor of Physics at MIT, co-author of the study on multiple superconducting states in graphene.
• Takafumi Sato — Researcher at Tohoku University's Advanced Institute for Materials Research (WPI-AIMR), lead author on the study creating stable 'boron graphene'.

👀 What to watch

• Further presentations and discussions from the 13th Aging Research & Drug Discovery (ARDD) Meeting at Harvard University, particularly on AI in drug discovery and future technologies.
• Updates on the docking of NASA's Crew-13 mission with the International Space Station.
• Additional data presentations from the European Academy of Dermatology and Venereology (EADV) Congress, especially regarding new dermatological treatments.